

# Review of: "Targeting Alzheimer's disease hallmarks with the Nrf2 activator Isoeugenol"

Fifteen Aprila Fajrin<sup>1</sup>

<sup>1</sup> Universitas Jember

**Potential competing interests:** No potential competing interests to declare.

I think this manuscript has already been written very well. But there are some questions I need to clarify with the authors:

1. The author needs to specify the title of the manuscript because it seems like a review, not original research.
2. Why did the author choose intranasal administration? Is eugenol inapplicable for oral or intravenous administration?
3. For the previous study, the author used eugenol at 50 mg/kg BW, but in the pharmacokinetics study, 100 mg/kg BW was used. Can you explain this?
4. For the in vivo testing, why did the author not use any drugs for Alzheimer's as the control? 5. In the behavioral studies, the author also used the hot plate for pain testing. I don't understand the purpose of this study in relation to your goal for eugenol as an anti-Alzheimer's agent. Would you please give a brief explanation?
6. The author needs to add some limitations of this study.
7. The conclusion must be straight to the point regarding the possibility of eugenol as a treatment for Alzheimer's disease.